Usefulness of barium sulfate and iohexol as contrast agents for VFSS in visualizing components of swallowing predictable of poor outcomes

Sci Rep. 2023 Dec 6;13(1):21556. doi: 10.1038/s41598-023-46297-4.

Abstract

Barium sulfate and iohexol are commonly used as contrast agents for videofluoroscopic swallowing study (VFSS). This study compared their usefulness as contrast agents in visualizing components of swallowing predictable of subsequent pneumonia and unintentional weight loss after VFSS. This was a randomized, controlled, crossover trial. The two contrast agents were alternately used in the same participants, and the order in which the contrast agent was tested first was randomly assigned. After VFSS, we followed the participants for 3 months and the association between VFSS findings of each contrast agent and the subsequent pneumonia and unintentional weight loss were analyzed. A total of 30 participants were included in the analysis. We recorded 11 cases of subsequent pneumonia and 13 of unintentional weight loss. Regarding the risk of subsequent pneumonia after VFSS, only the oral transit time and number of swallows tested with barium sulfate indicated significant differences between participants with and without subsequent pneumonia. For unintentional weight loss, oral transit time and pharyngeal wall coating after swallowing tested with barium sulfate, as well as oral transit time, nasal penetration, residue in the valleculae, PAS scores, and number of swallows when testing with iohexol demonstrated significant differences between those with and without unintentional weight loss.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Barium Sulfate
  • Contrast Media
  • Cross-Over Studies
  • Deglutition
  • Deglutition Disorders* / diagnostic imaging
  • Fluoroscopy
  • Humans
  • Iohexol
  • Pneumonia*
  • Video Recording
  • Weight Loss

Substances

  • Barium Sulfate
  • Contrast Media
  • Iohexol